Literature DB >> 31483959

Medicare Drug-Price Negotiation - Why Now . . . and How.

Richard G Frank1, Len M Nichols1.   

Abstract

Mesh：

Year:  2019        PMID： 31483959     DOI： 10.1056/NEJMp1909798

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.

Authors:  Andrew Sumarsono; Muthiah Vaduganathan; Ezimamaka Ajufo; Ann Marie Navar; Gregg C Fonarow; Sandeep R Das; Ambarish Pandey
Journal:  JAMA Cardiol       Date:  2020-03-01       Impact factor: 14.676

2.  Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Authors:  Alyssa Bilinski; Evan MacKay; Joshua A Salomon; Ankur Pandya
Journal:  Value Health       Date:  2022-02-24       Impact factor: 5.101

3.  Value-based drug pricing in the Biden era: Opportunities and prospects.

Authors:  Peter J Neumann; Daniel A Ollendorf; Joshua T Cohen
Journal:  Health Serv Res       Date:  2021-06-03       Impact factor: 3.734

4.  Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.

Authors:  Chien-Wen Tseng; R Adams Dudley; Randi Chen; Rochelle P Walensky
Journal:  JAMA Netw Open       Date:  2020-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.